The evidence behind inhibitor treatment with recombinant factor VIIa

Pathophysiology of Haemostasis and Thrombosis

Volumn 32, Issue SUPPL. 1, 2002, Pages 13-18

  Ludlam, Christopher A ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Bolus dose; Continuous infusion; Haemostatic response; rFVIIA

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; ALLOANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

BLEEDING; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EMERGENCY; EVIDENCE BASED MEDICINE; HALF LIFE TIME; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; BLOOD; HEMOPHILIA A; IMMUNOLOGY; REVIEW;

AUTOANTIBODIES; BLOOD COAGULATION FACTORS; EVIDENCE-BASED MEDICINE; FACTOR VII; HEMOPHILIA A; HEMORRHAGE; HUMANS; ISOANTIBODIES; RECOMBINANT PROTEINS;

EID: 19044365519     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057294     Document Type: Conference Paper

References (20)

1. Hedner U, Kristensen H, Berntorp E, Ljung R, Petrini P, Tengborn L: Pharmacokinetics of rFVIIa in children. Haemophilia 1998;4:244 (abstract).
2. Ingerslev J, Freidman D, Gasstineau D, Gilchrist G, Johnsson H, Lucas G, McPherson J, Preston E, Scheibel E, Shuman M: Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996;26:118-123.
3. McPherson J, Teague L, Lloyd J, Jupe D, Rowell J, Ockelford P, Ekert H, Street A, Faase A, Hedner U: Experience with recombinant factor VIIa in Australia and New Zealand. Haemostasis 1996;26:109-117.
4. Scharrer I: Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999;5:253-259.
5. Arkin S, Blei F, Fetten J, Foulke R, Gilchrist GS, Heisel MA, Key N, Kisker CT, Kitchen C, Shafer FE, Shah PC, Strickland D: Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: Results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors Blood Coagul Fibrinolysis 2000;11:255-259.
6. Liebman HA, Chediak J, Fink KI, Gahvez AG, Shah PC, Shann RL: Activated recombinant human coagulation factor VII therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol 2000; 63:109-113.
7. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, Laurian Y, Kasper CK, Mannucci PM: A randomised, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucotaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia 1998;4:790-798.
8. Ingerslev J, Thykjaer H, Kudsk Jensen O, Fredberg U: Home treatment with recombinant factor VII: results from one centre. Blood Coagul Fibrinolysis 1998;9(suppl 1):107-110.
9. Santagostino E, Gingen A, Mannucci PM: Home treatment with rccombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999;104:22-26.
10. Laurian Y, Goudemand J, Négrier C et al: Use of recombinant activated factor VII as first line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors. Blood Coagul Fibrinolysis 1998;9(suppl 1):155-156.
11. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E: Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912-918.
12. Hay CRM, Negrier C, Ludlam CA: The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study. Thromb Haemost 1997;78:1463-1467.
13. Smith OP, IM Hann: rVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors. Br J Haematol 1996;92:1002-1004.
14. Shapiro AD, Gilchrist GS, Hoots WK, Cooper A, Gastineau DA: Prospective, Randomised Trial of Two Doses of fFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery, Thromb Haemost 1998;80:773-778.
15. Santagostino E, Morfini M, Rocino A, Scaraggi FA, Gingen A: Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001;86:954-958.
16. Smith MP, Ludlam CA, Collins PW, Hay CR, Wilde JT, Gingeri A, Melsen T, Savidge GF: Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: Plasma factor VII activity of 10 IU/ml Is associated with an increased incidence of bleeding. Thromb Haemost 2001;86:949-953.
17. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GT: A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: A pharmacokinetic and efficacy evaluation. In preparation.
18. Novo Nordisk data on file: Investigator's Brochure; Recombinant Coagulation Factor VIIa 10th Edition, 20 March 2001.
19. Bajzar I, Manuel R, Neshiem ME: Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-14484.
20. Proulle V, Hugel B, Gulliet B, Rafowicz A, d'Oiron R, Lambet T, Tchernia G, Freyssinet JM, Dreyfus M: Circulating microparticles as a marker of recombinant activated FVII (Novo-Seven) efficacy in patients with FVIII or FIX inhibitors. J Thromb Haemost 2001(suppl): OC1771 (abstract).